- 2022.06.10
- News
- [In the Media] AMR Alliance Japan Presents Recommendations for the Basic Policy on Economic and Fiscal Management and Reform to Advance AMR Control (The Nikkan Yakugyo, May 30, 2022)
- 2022.06.07
- News
- [Activity Report] Humanitarian Congress Tokyo 2022 Session 1 – “Time to face the ‘Silent Pandemic’ of AMR – Roles of Medical and Humanitarian Actors” (May 19, 2022)
- 2022.05.30
- News
- [Urgent Recommendation] Recommendation for the Basic Policy on Economic and Fiscal Management and Reform 2022 (May 30, 2022)
- 2022.04.27
- News
- [Activity Report] Launch of New Website by AMED Public and Private Partnerships for Infectious Disease R&D (April 14, 2022)
- 2022.04.25
- News
- [Activity Report] Himeji City becomes first municipality in Japan to issue declaration on the promotion of AMR countermeasures (February 21, 2022)
- 2022.04.15
- Event
- [Registration Closed] Japanese Society of Antimicrobials for Animals – The 48th Symposium (April 23, 2022)
- 2022.04.11
- Event
- [Registration Closed] (Webinar) Making the ‘Silent Pandemic’ of AMR Heard: What Countries Leading the Charge Against AMR are Doing to Ensure their Populations are Protected (April 28, 2022)
- 2022.04.07
- Event
- [Event Report] WHO Regional Committee for the Western Pacific Related Event: “AMR: A Global Health Crisis” (September 25, 2021)
- 2022.03.31
- News
- [Case Study] Koji Masuda and Kenji Ikeda “TDM Is Not Only for Safety, but for Ensuring Effectiveness” (March 31, 2022)
- 2022.03.18
- News
- [Patient’s Voice] Ms. Sachiko Ito – Non-Tuberculosis Mycobacterial Lung Disease (March 18, 2022)
- 2022.03.17
- Event
- [Activity Report] Submission of recommendations to Public Comment on the “Interim Report of the Global Health Strategy in Japan Toward the 2030 Sustainable Development Goals (SDGs)” (March 17, 2022)
- 2022.03.07
- News
- [Case Study] Keisuke Kagami and Mitsuru Sugawara “Thrombocytopenia Can be Avoided By Monitoring Linezolid Blood Levels – Enabling Long-Term Linezolid Use for the Successful Treatment of Refractory Pyogenic Spondylodiscitis” (March 7, 2022)
- 2022.02.22
- News
- [Case Study] Keisuke Kagami and Mitsuru Sugawara “Concomitant piperacillin-tazobactam and vancomycin use increases the risk of acute kidney injury.” (AMR Alliance Japan, February 22, 2022)
- 2022.01.14
- News
- [In the Media] “Faster Response to Antimicrobial Resistant Bacteria” (The Nikkei Personal Opinion and Insight, December 20, 2021)
- 2021.12.27
- Event
- [Event Report] The Third Meeting of Working Group 3 Under the Sub-committee on AMR of the Nikkei FT Communicable Diseases Conference Asia Africa Medical Innovation Consortium (AMIC) (December 17, 2021)
- 2021.12.23
- Event
- [Event Report] FY2022 AMR Alliance Japan Planning Meeting (December 6, 2021)
- 2021.12.22
- News
- [Case Study] Akari Shigemi “The importance of proper antimicrobial use for MRSA infections – Beware of rifampicin monotherapy induced resistance” (December 22, 2021)
- 2021.12.02
- News
- [Publication Report] Incentivizing Resilience: Accelerating Efforts to Promote the Research and Development Needed to Save the World from the Next Pandemic (December 2, 2021)
- 2021.12.02
- Event
- [Event Report] Investing in the Future: The Role of Investors in Saving the World from AMR (September 8, 2021)
- 2021.11.26
- News
- [Research Report] Nearly 60% Would Pay More for New Antibiotics – Although knowledge of the threat of AMR remains low, new HGPI poll suggests that Japanese public would be willing to consider further financial support for new antibiotics (November 26, 2021)
